February 14, 2024
Iaterion, Inc. received financing of undisclosed amount from Capital K, a venture capital fund in Silicon Valley, California

Iaterion, Inc. is developing novel therapeutics for Women’s Health and Oncology. Current funding is aimed to advance their novel drug MF5 for the treatment of menopausal symptoms and the prevention of breast cancer and IAONC105 for the treatment of advanced triple negative breast cancer.

“We are excited to partner with Iaterion and its team on the development of its novel drugs”, said Patrick Suel, Managing Director of Capital K. “Iaterion has a very promising approach to advancing novel therapies for women, an area unfortunately neglected in the past few decades. We are excited to be at the forefront of a new era in Women’s Health.”

“Very little novel innovative approaches in women’s health have been advanced in the past few decades” said Dr. Isaac Cohen, Iaterion’s CEO. “More so, of the $200 billion annual investment in biomedical R&D only 1% goes to women’s health. This is despite the fact that half the world’s population is female, and women encounter gender specific diseases and gender specific differences in disease presentation and experience. Iaterion is aiming to change current landscape by introducing novel discoveries and advancing the unique understanding related to female pathophysiology by promoting new therapies”.

Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Iaterion, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Iaterion, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.